Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need.
Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health.
Welcome to the 13th edition of the European Hidradenitis Suppurativa Foundation Conference in Lyon!
With the emergence of innovative biologics, combined with surgical strategies, the HS community is undergoing a remarkable revolution. The EHSF is the congress to discuss cutting edge data and emergent therapeutic strategies in HS; with the latest revelations in clinical and fundamental research, or the most ardent debates on diagnostic and treatments.
There is indeed still so much to be done to improve the care of HS patients! This meeting will be a wonderful opportunity for scientists, caregivers and patients to connect in a multidisciplinary hub.
With Lyon hosting the EHSF, attendees will enjoy exciting social programs, the warmest hospitality, and the most exquisite traditional French cuisine.
We are delighted and honored to host the 13th EHSF in Lyon, eagerly anticipating your passionate response to these fundamental issues.
Axel VILLANI, MD, PhD
Professor
Philippe GUILLEM, MD, PhD
